TY - JOUR AU - Zhang, Yaqiong AU - Li, Bo AU - Sun, Qianqian AU - Wu, Xiaoyu AU - Chen, Qi AU - Li, Zhaoyun AU - Mo, Jinggang PY - 2017 TI - Association between APC promoter methylation and clinicopathological features of patients with hepatocellular carcinoma: a meta-analysis with PRISMA guideline JF - Translational Cancer Research; Vol 6, No 2 (April 28, 2017): Translational Cancer Research Y2 - 2017 KW - N2 - Background: The adenomatous polyposis coli ( APC ) has been reported as a key tumor suppressor gene in hepatocellular carcinoma (HCC). However, the clinical significance of APC promoter methylation in HCC remains unclear. This meta-analysis was conducted to assess the relationship between APC promoter methylation and clinicopathological characteristics of patients with HCC. Methods: Eligible publications were identified by online electronic databases (PubMed, Embase, EBSCO and the Cochrane Library). The combined odds ratios (ORs) with their corresponding 95% confidence intervals (95% CIs) were calculated and summarized under the random-effects model. Results: Final 21 available studies were included in the current study. APC promoter methylation was significantly higher in HCC than in normal live tissues, liver cirrhosis, and healthy blood samples (OR=11.46, P 0.1). APC promoter methylation was shown to be associated with hepatitis B virus (HBV), and hepatitis C virus (HCV) infection status of patients with HCC (OR=2.86, P=0.005; OR=3.50, P=0.001; respectively), but not correlated with clinical stage, gender, and vascular invasion status (P>0.1). Conclusions: APC promoter methylation may be correlated with HCC, especially for patients with HBV and HCV infection status. Promoter methylation of the APC may be a potential noninvasive biomarker using blood samples in the detection of HCC. More studies with large samples sizes are needed to validate our findings in the future. UR - https://tcr.amegroups.org/article/view/13100